85. Cheskin LJ. Commentary: A personal-contact weight-loss maintenance intervention reduced weight regain in overweight and obese adults. ACP Journal Club, 2008.
80. Cheskin LJ, Mitchell AM, *Jhaveri AD, *Mitola AH, *Davis LM, Lewis RA, Yep MA, *Lycan TW. Efficacy of meal replacements versus standard food-based diet for weight loss in type 2 diabetes: A controlled clinical trial. The Diabetes Educator 34(1):118-127, 2008.
81. Beydoun MA, Gary TL, Caballero BH, Lawrence RS, Cheskin LJ, Wang Y. Ethnic differences in dairy and related nutrient consumption among US adults and their association with obesity, central obesity, and the metabolic syndrome Am J Clin Nutr 87:1914 –25, 2008
82. Cheskin LJ, *Davis LM, *Mitola AH, *Lipsky LM, *Lycan T, *Mitchell V, *Mickle B, *Adkins E. Lack of energy compensation over 4 days when white button mushrooms are substituted for beef. Appetite, in press, 2008.
77. Cheskin LJ, *Prosser BJ. Obesity and the risk of colon polyps. J Clin Gastroenterol 41(3):229-30, 2007.
78. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney International, Oct 10, 2007.
79. *Pollack KM, Cheskin LJ. Obesity and workplace traumatic injury: does the science support the link? Inj Prev. 13(5):297-302, 2007.
74. Neuhouser M, Rock CL, Kristal AR, Patterson RE, Neumark-Sztainer D, Cheskin LJ, Thornquist MD. Olestra is associated with slight reductions in serum carotenoids but does not markedly influence serum fat-soluble vitamin concentrations. Am J Clin Nutr. 83(3):624-31, 2006.
75. *Sidhaye A, Cheskin LJ. Pharmacologic treatment of obesity. Adv Psychosomatic Med 27:42-52, 2006.
76. *Davis LM, Pei Z, Trush MA, Cheskin LJ, Contoreggi C, McCullough K, Watkins PA, Moran TH. Bromocriptine reduces steatosis in obese rodent models. J Hepatology 45(3):439-44, 2006.
73. Cheskin LJ, Hess JM, Henningfield J, Gorelick DA. Caloric restriction increases cigarette use in smokers. Psychopharmacology: 179:430-6, 2005.
71. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange RW, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 75(1):34-48, 2004.
72. Subramanian PS, Goldenberg-Cohen N, Shukla S, Cheskin LJ, Miller NR. Plasma ghrelin levels in obese patients with idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 138(1):109-13, 2004.
67. Cheskin LJ, Mitchell AM. Commentary: Review: Oral protein and energy supplements reduce all-cause mortality in elderly persons. ACP J Club 138(3):59, 2003.
68. Cheskin LJ. Managing the overweight neurology patient: clinical strategies. Advanced Studies in Medicine 3(6A):S494-498, 2003.
69. Satia-Abouta J, Kristal A, Patterson RE, Neuhouser M, Peters JC, Rock CL, Neumark-Sztainer D, Cheskin LJ, Thornquist MD. Is olestra consumption associated with changes in dietary intake, serum lipids, and body weight? Nutrition 19:754-9, 2003.
70. Cheskin LJ, Gittelsohn J. In Focus: The Obesity Epidemic. Obesity as a future healthcare nightmare: Can health policy provide the cure? Harvard Health Policy Rev 4(2):56-61, 2003.
65. Neuhouser ML, *Miller DL, Kristal AR, Barnett MJ, Cheskin, LJ. Diet and exercise habits of patients with diabetes, dyslipidemia, cardiovascular disease or hypertension. J Am Coll Nutr 21(5): 394-401, 2002.
66. Cheskin LJ. Commentary: Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons. ACP J Club 136(2):49, 2002.
.